88 related articles for article (PubMed ID: 23046363)
1. Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content.
Thallas-Bonke V; Coughlan MT; Tan AL; Harcourt BE; Morgan PE; Davies MJ; Bach LA; Cooper ME; Forbes JM
Nephrology (Carlton); 2013 Jan; 18(1):47-56. PubMed ID: 23046363
[TBL] [Abstract][Full Text] [Related]
2. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy.
Tan AL; Sourris KC; Harcourt BE; Thallas-Bonke V; Penfold S; Andrikopoulos S; Thomas MC; O'Brien RC; Bierhaus A; Cooper ME; Forbes JM; Coughlan MT
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F763-70. PubMed ID: 20015941
[TBL] [Abstract][Full Text] [Related]
3. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.
Lassila M; Seah KK; Allen TJ; Thallas V; Thomas MC; Candido R; Burns WC; Forbes JM; Calkin AC; Cooper ME; Jandeleit-Dahm KA
J Am Soc Nephrol; 2004 Aug; 15(8):2125-38. PubMed ID: 15284298
[TBL] [Abstract][Full Text] [Related]
4. Gene expression of receptor for advanced glycosylation end products and its modulation by aminoguanidine in diabetic kidney tissue.
Huang Y; Lin S; Zhou J
Chin Med J (Engl); 1998 Aug; 111(8):698-704. PubMed ID: 11245022
[TBL] [Abstract][Full Text] [Related]
5. Targeted reduction of advanced glycation improves renal function in obesity.
Harcourt BE; Sourris KC; Coughlan MT; Walker KZ; Dougherty SL; Andrikopoulos S; Morley AL; Thallas-Bonke V; Chand V; Penfold SA; de Courten MP; Thomas MC; Kingwell BA; Bierhaus A; Cooper ME; de Courten B; Forbes JM
Kidney Int; 2011 Jul; 80(2):190-8. PubMed ID: 21412218
[TBL] [Abstract][Full Text] [Related]
6. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin.
Myint KM; Yamamoto Y; Doi T; Kato I; Harashima A; Yonekura H; Watanabe T; Shinohara H; Takeuchi M; Tsuneyama K; Hashimoto N; Asano M; Takasawa S; Okamoto H; Yamamoto H
Diabetes; 2006 Sep; 55(9):2510-22. PubMed ID: 16936199
[TBL] [Abstract][Full Text] [Related]
7. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy.
Wendt TM; Tanji N; Guo J; Kislinger TR; Qu W; Lu Y; Bucciarelli LG; Rong LL; Moser B; Markowitz GS; Stein G; Bierhaus A; Liliensiek B; Arnold B; Nawroth PP; Stern DM; D'Agati VD; Schmidt AM
Am J Pathol; 2003 Apr; 162(4):1123-37. PubMed ID: 12651605
[TBL] [Abstract][Full Text] [Related]
8. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products.
Zheng F; He C; Cai W; Hattori M; Steffes M; Vlassara H
Diabetes Metab Res Rev; 2002; 18(3):224-37. PubMed ID: 12112941
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway.
Thallas-Bonke V; Thorpe SR; Coughlan MT; Fukami K; Yap FY; Sourris KC; Penfold SA; Bach LA; Cooper ME; Forbes JM
Diabetes; 2008 Feb; 57(2):460-9. PubMed ID: 17959934
[TBL] [Abstract][Full Text] [Related]
10. Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice.
Jensen LJ; Denner L; Schrijvers BF; Tilton RG; Rasch R; Flyvbjerg A
J Endocrinol; 2006 Mar; 188(3):493-501. PubMed ID: 16522729
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products.
Kaji Y; Usui T; Ishida S; Yamashiro K; Moore TC; Moore J; Yamamoto Y; Yamamoto H; Adamis AP
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):858-65. PubMed ID: 17251488
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE).
Oldfield MD; Bach LA; Forbes JM; Nikolic-Paterson D; McRobert A; Thallas V; Atkins RC; Osicka T; Jerums G; Cooper ME
J Clin Invest; 2001 Dec; 108(12):1853-63. PubMed ID: 11748269
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis.
Ihara Y; Egashira K; Nakano K; Ohtani K; Kubo M; Koga J; Iwai M; Horiuchi M; Gang Z; Yamagishi S; Sunagawa K
J Mol Cell Cardiol; 2007 Oct; 43(4):455-64. PubMed ID: 17761193
[TBL] [Abstract][Full Text] [Related]
14. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.
Sugimoto H; Grahovac G; Zeisberg M; Kalluri R
Diabetes; 2007 Jul; 56(7):1825-33. PubMed ID: 17456853
[TBL] [Abstract][Full Text] [Related]
15. Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells.
Tsuji H; Iehara N; Masegi T; Imura M; Ohkawa J; Arai H; Ishii K; Kita T; Doi T
Biochem Biophys Res Commun; 1998 Apr; 245(2):583-8. PubMed ID: 9571198
[TBL] [Abstract][Full Text] [Related]
16. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice.
Yamamoto Y; Kato I; Doi T; Yonekura H; Ohashi S; Takeuchi M; Watanabe T; Yamagishi S; Sakurai S; Takasawa S; Okamoto H; Yamamoto H
J Clin Invest; 2001 Jul; 108(2):261-8. PubMed ID: 11457879
[TBL] [Abstract][Full Text] [Related]
17. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes.
Shoji T; Koyama H; Morioka T; Tanaka S; Kizu A; Motoyama K; Mori K; Fukumoto S; Shioi A; Shimogaito N; Takeuchi M; Yamamoto Y; Yonekura H; Yamamoto H; Nishizawa Y
Diabetes; 2006 Aug; 55(8):2245-55. PubMed ID: 16873687
[TBL] [Abstract][Full Text] [Related]
18. The RAGE axis in early diabetic retinopathy.
Barile GR; Pachydaki SI; Tari SR; Lee SE; Donmoyer CM; Ma W; Rong LL; Buciarelli LG; Wendt T; Hörig H; Hudson BI; Qu W; Weinberg AD; Yan SF; Schmidt AM
Invest Ophthalmol Vis Sci; 2005 Aug; 46(8):2916-24. PubMed ID: 16043866
[TBL] [Abstract][Full Text] [Related]
19. Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes.
Tesch G; Sourris KC; Summers SA; McCarthy D; Ward MS; Borg DJ; Gallo LA; Fotheringham AK; Pettit AR; Yap FY; Harcourt BE; Tan AL; Kausman JY; Nikolic-Paterson D; Kitching AR; Forbes JM
Diabetologia; 2014 Sep; 57(9):1977-85. PubMed ID: 24957662
[TBL] [Abstract][Full Text] [Related]
20. Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.
Nishizawa Y; Koyama H
J Ren Nutr; 2008 Jan; 18(1):76-82. PubMed ID: 18089449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
